Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options 17 July 2015 click to view Press Release In this Press Release: Health Risk(s): HIV Product Type(s): Microbicides MPTs Vaccines Topic(s): Advocacy Funding
Continue reading